RE:RE:RE:SoleusExcellent point. I can't remember the details on who was prescient enough to realize that what IMMU had was worth a whole lot more to develop on their own (mgmt or shareholders), but it created massively more value for shareholders. Maybe it was when they were stumbling around with pretty severe safety issues.
I think it's fair to say that what Gilead paid did incorporate a lot of the potential around new indications, new conjugates, new partnerships and the like. That's fair. Analysts felt Gilead needed to get the EBITDA for all the compounds around Trodelvy/TROP-2 up to around $5-6bil in order to justify the $21bil price tag. They're close to their second IND/usage, so begining to build toward that but still a long way to go.
SPCEO1 wrote: We have to hope that our interests are always pretty tightly aligned with Soleus' and I suspect they mostly always will be. The one risk is if they need a quick win at some point and try to organize an earlier than needed sale of the company where it meets some immediate goal of theirs but sells TH at a price than is significantly less than we might had achieved if they did not sell. Having been through so many twists and turns with TH over the years, it would not surprise me at all if we at some point face what the Immnuomedics shareholders once faced when the company was almost sold to early on them to SeaGen.
Wino115 wrote: The genesis of the firm is that they were the healthcare team for Paulson and, from what I heard, were the sole bright spot over a number of years and essentially were responsible for the majority of the overall firms positive results. They spun out on their own. The only way to see is to go back and look at some of their larger holders that are part of filings (on Edgar).
I think for our purposes it is also interesting to see if they have identified early themes and taken private stakes that ultimately led to either an IPO of industry sale at nice profits for them. You'd have to also look at filings and companies where they have Board seats. Spots like Whaleinvestor or whatever that site is called can be helpful.
The one we know of from last year is BioAtla which went public. It hasn't done that great since the IPO, but I'm sure they made 10x their money or something like that and likely sold some in the IPO or soon after. The healthcare merchant bank fund CEO I spoke to once about the 4 new investors rated them very highly in knowledge, past success and as an investment partner. He rated Armistice as "short-term traders, not investors" too, and that was bang-on.
palinc2000 wrote: Mission"
The Firm seeks to generate superior risk-adjusted returns through idiosyncratic, catalyst-driven investing with a focus on complex and niche opportunities in the Public and Private space.
I find it interesting that they have increased theur hokdings in THTX during the last Quarter,,....Obviously they are not risk adverse but I am trying to see their record in early stage biotechs and see how successful they have been in being ahead of the curve but did not find much .......,,,Anyone???